Log in to your Inderes Free account to see all free content on this page.

Iconovo

1.11 SEK

-3.48 %

Less than 1K followers

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-3.48 %

-21.83 %

-53.56 %

-44.50 %

-70.39 %

-71.22 %

-97.52 %

-97.64 %

-96.59 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Market cap

83.03M SEK

Turnover

21.24K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

27.2.

2026

Annual report '25

All

Press releases

ShowingAll content types

Regulatory press release13 hours ago

Nomination Committee appointed at Iconovo AB

Regulatory press release12/16/2025, 11:45 AM

Iconovo announces that the terms and conditions for allotment of shares in directed issue are met

Press release11/26/2025, 11:47 AM

DNB Carnegie Access: Iconovo: Raises capital

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/25/2025, 8:05 PM

Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments

Press release10/31/2025, 10:21 AM

DNB Carnegie Access: Iconovo: New interim CEO appointed

Regulatory press release10/31/2025, 8:35 AM

Iconovo appoints new CEO

Press release10/27/2025, 1:13 PM

Redeye: Iconovo (Q3 Review) - An uneventful quarter with solid cost-cutting

Press release10/27/2025, 8:00 AM

DNB Carnegie Access: Iconovo - Rapportintervju Q3(25)

Press release10/24/2025, 4:16 PM

DNB Carnegie Access: Iconovo: Costs down, focus sharpened – Q3 review

Regulatory press release10/24/2025, 6:30 AM

QUARTERLY REPORT Q3 2025

Press release10/14/2025, 2:26 PM

DNB Carnegie Access: Iconovo: Financial targets withdrawn

Regulatory press release10/14/2025, 1:37 PM

Iconovo reworks its strategic goals

Regulatory press release8/13/2025, 2:00 PM

Iconovo AB changes Certified Adviser to Tapper Partners AB

Press release7/15/2025, 8:37 AM

Redeye: Iconovo Q2 - An undramatic report with early signs of cost reductions

Press release7/15/2025, 5:30 AM

DNB Carnegie Access: Iconovo: Quiet Q2 but funded with a stronger ownership base

Regulatory press release7/14/2025, 6:30 AM

QUARTERLY REPORT Q2 2025

Regulatory press release6/11/2025, 2:45 PM

Iconovo’s rights issue is registered – conversion of BTA into shares

Press release6/11/2025, 6:30 AM

Iconovo’s development of intranasal GLP-1 for a more convenient treatment of obesity is making significant progress

Regulatory press release6/9/2025, 6:15 AM

Iconovo's nomination committee proposes the election of Christer Fåhraeus as new board member

Regulatory press release6/3/2025, 2:42 PM

Iconovo announces final outcome in the rights issue

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.